Berberine 用于 肠道菌群失调
D 研究 目前仅存在初步研究（实验室研究、病例报告）。Preclinical evidence that berberine modulates microbiome composition. Limited human microbiome data.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dberberine\u0026condition\u003Dgut\u002Ddysbiosis';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
D
结论
Preclinical evidence that berberine modulates microbiome composition. Limited human microbiome data.
Key Study Findings
In Vitro
Colon-targeted self-assembled nanoparticles loaded with berberine double salt ameliorate ulcerative colitis by improving intestinal mucosal …
Dose: None
vs: Sulfasalazine; DSS-induced UC mice
Outcome: UC treatment efficacy
效果: Colon length 1.2x longer than sulfasalazine
None
研究人群: DSS-induced UC murine model
Review
Gut Microbiota-Targeted Therapeutics for Metabolic Disorders: Mechanistic Insights into the Synergy of Probiotic-Fermented Herbal Bioactives.
Dose: None
vs: None
Outcome: None
效果: None
None
研究人群: None
Review
Perspectives on Berberine and the Regulation of Gut Microbiota: As an Anti-Inflammatory Agent.
Dose: None
vs: None
Outcome: None
效果: None
None
研究人群: None
Review
Natural Bioactive Compounds in the Management of Type 2 Diabetes and Metabolic (Dysfunction)-Associated Steatotic Liver …
Dose: None
vs: None
Outcome: None
效果: None
None
研究人群: None
Other
Design and Activity Evaluation of Berberine-Loaded Dual pH and Enzyme-Sensitive Colon-Targeting Microparticles.
Dose: None
vs: Free berberine; DSS-induced UC model vs normal mice
Outcome: DAI scores, inflammatory cytokines, gut microbiota
效果: None
<0.01 (DAI); <0.05 (cytokines)
研究人群: DSS-induced UC mouse model (male KM mice)
Other
Ulcerative Colitis Aggravates Periodontitis via Inducing Myelopoiesis.
Dose: None
vs: DSS-induced colitis + periodontitis mouse models
Outcome: Periodontal destruction and myeloid cell generation
效果: None
None
研究人群: DSS-induced colitis with periodontitis mouse model
Key Statistics
2
研究数量
100
受试者
↑
Positive
D
等级
Referenced Papers
International journal of …
2025
15 次引用
Colloids and surfaces. …
2025
11 次引用
Pharmaceuticals (Basel, Switzerland)
2025
8 次引用
Perspectives on Berberine and the Regulation of Gut Microbiota: As an Anti-Inflammatory Agent.
Review
Pharmaceuticals (Basel, Switzerland)
2025
8 次引用
Inflammatory bowel diseases
2025
2 次引用
Pharmaceutics
2025
2 次引用
Phytomedicine : international …
2025
2 次引用
The Journal of …
2025
1 次引用
European journal of …
2025
Archives of oral …
2025
Frontiers in nutrition
2025
Biomedicine & pharmacotherapy …
2024
17 次引用
Berberine Effects in Pre-Fibrotic Stages of Non-Alcoholic Fatty Liver Disease-Clinical and Pre-Clinical Overview and Systematic Review of the Literature.
Systematic Review
International journal of …
2024
14 次引用
Frontiers in pharmacology
2024
9 次引用
Hepatology communications
2024
9 次引用
Frontiers in microbiology
2024
6 次引用
Frontiers in microbiology
2024
5 次引用
Indian journal of …
2024
2 次引用
Gut microbes
2023
108 次引用
Biomedicine & pharmacotherapy …
2023
61 次引用
International journal of …
2023
48 次引用
Journal of ethnopharmacology
2023
29 次引用
Frontiers in pharmacology
2023
20 次引用
International journal of …
2023
18 次引用
Current pharmaceutical design
2023
10 次引用
Journal of oral …
2023
10 次引用
Journal of neurogastroenterology …
2023
4 次引用
Berberine interacts with gut microbiota and its potential therapy for polycystic ovary syndrome.
Review
Clinical and experimental …
2023
2 次引用
Microorganisms
2022
212 次引用
Food & function
2022
83 次引用
Phytomedicine : international …
2022
67 次引用
Biomaterials science
2022
34 次引用
Microbiology spectrum
2022
25 次引用
Brazilian journal of …
2022
12 次引用
Pharmacological research
2021
186 次引用
Pharmacological research
2021
147 次引用
Acta pharmacologica Sinica
2021
63 次引用
Frontiers in pharmacology
2021
42 次引用
Frontiers in immunology
2021
22 次引用
Comprehensive Physiology
2021
21 次引用
International journal of …
2021
20 次引用
Targeting gut barrier dysfunction with phytotherapies: Effective strategy against chronic diseases.
Review
Pharmacological research
2020
65 次引用
Berberine for prevention of dementia associated with diabetes and its comorbidities: A systematic review.
Systematic Review
Journal of integrative …
2020
33 次引用
Pharmacological research
2019
166 次引用
American journal of …
2019
117 次引用
Biomedicine & pharmacotherapy …
2019
72 次引用
Scientific reports
2019
51 次引用
Pharmacological research
2019
31 次引用
Science China. Life …
2018
17 次引用
Alternative therapies in …
2017
9 次引用
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
常用剂量
- general:
- 500-1,500 mg/day in divided doses
- siboprotocol:
- 500 mg two to three times daily for 4 weeks (as part of herbal antimicrobial protocol)
- giantimicrobial:
- 500 mg twice daily
上限： Generally well-tolerated up to 1,500 mg/day in divided doses
研究中使用的剂量
| 剂量 | 持续时间 | 效果 | N |
|---|---|---|---|
| None | -- | Positive | -- |
| None | -- | Mixed | -- |
| None | -- | Mixed | -- |
| None | -- | Mixed | -- |
| None | -- | Positive | -- |
| None | -- | Positive | -- |
| None | -- | Positive | -- |
| None | 6 weeks | Positive | -- |
最佳服用时间： With meals; divide doses throughout the day (do not take full daily dose at once)
Safety & Side Effects
已报告的副作用
- ⚠ GI side effects (diarrhea, constipation, flatulence, abdominal pain) — most common
- ⚠ May cause uterine contractions (contraindicated in pregnancy)
- ⚠ Headache
- ⚠ Skin rash (rare)
已知相互作用
- ● Diabetes medications (berberine significantly lowers blood sugar; risk of hypoglycemia)
- ● Cyclosporine (berberine inhibits CYP3A4, increasing cyclosporine levels)
- ● Anticoagulants (may have additive blood-thinning effects)
- ● Metformin (additive glucose-lowering effect; monitor closely)
- ● Macrolide antibiotics (berberine inhibits CYP3A4)
可耐受最高摄入量： Generally well-tolerated up to 1,500 mg/day in divided doses
在开始服用任何补充剂之前，请务必咨询您的医疗保健提供者。
Frequently Asked Questions
Does Berberine help with 肠道菌群失调?
Based on 2 studies with 100 participants, there is preliminary evidence that needs more research that Berberine may support 肠道菌群失调 management. Our evidence grade is D (Very Early Research).
How much Berberine should I take for 肠道菌群失调?
Studies have used various dosages. A commonly studied range is 500-1,500 mg/day in divided doses. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Berberine?
Reported side effects may include GI side effects (diarrhea, constipation, flatulence, abdominal pain) — most common, May cause uterine contractions (contraindicated in pregnancy), Headache, Skin rash (rare). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Berberine and 肠道菌群失调?
We rate the evidence as Grade D (Very Early Research). This rating is based on 2 peer-reviewed studies with 100 total participants. The overall direction of effect is positive.
Related Evidence
其他成分用于 肠道菌群失调
Berberine 用于其他健康状况
References
- [1] Yue Fan et al.. Int J Mol Sci. 2025. Gut Microbiota-Targeted Therapeutics for Metabolic Disorders: Mechanistic Insights into the Synergy of Probiotic-Fermented Herbal Bioactives. doi:10.3390/ijms26125486 PubMed
- [2] Yalong Wang et al.. Colloids Surf B Biointerfaces. 2025. Colon-targeted self-assembled nanoparticles loaded with berberine double salt ameliorate ulcerative colitis by improving intestinal mucosal barrier and gut microbiota. doi:10.1016/j.colsurfb.2024.114353 PubMed
- [3] Daniela Ciobârcă et al.. Pharmaceuticals (Basel). 2025. Natural Bioactive Compounds in the Management of Type 2 Diabetes and Metabolic (Dysfunction)-Associated Steatotic Liver Disease. doi:10.3390/ph18020279 PubMed
- [4] Quintero Vargas Jael Teresa de Jesús et al.. Pharmaceuticals (Basel). 2025. Perspectives on Berberine and the Regulation of Gut Microbiota: As an Anti-Inflammatory Agent. doi:10.3390/ph18020193 PubMed
- [5] Xinyi Kuang et al.. Inflamm Bowel Dis. 2025. Ulcerative Colitis Aggravates Periodontitis via Inducing Myelopoiesis. doi:10.1093/ibd/izaf150 PubMed
- [6] Jingqi Sun et al.. Pharmaceutics. 2025. Design and Activity Evaluation of Berberine-Loaded Dual pH and Enzyme-Sensitive Colon-Targeting Microparticles. doi:10.3390/pharmaceutics17060778 PubMed
- [7] Xiaoyu Tao et al.. Phytomedicine. 2025. Co-administration of berberine and evodiamine: Mitigating evodiamine-induced hepatotoxicity and potentiating colitis treatment. doi:10.1016/j.phymed.2025.157185 PubMed
- [8] Jiahui Xu et al.. J Nutr Biochem. 2025. Berberine alleviates metabolic dysfunction-associated steatohepatitis by enhancing the abundance of Akkermansia muciniphila. doi:10.1016/j.jnutbio.2025.110069 PubMed
- [9] Wenwen Tan et al.. Eur J Pharmacol. 2025. Oxyberberine alleviates fructose-induced hyperuricemia by modulating purine metabolism and gut microbiota. doi:10.1016/j.ejphar.2025.178061 PubMed
- [10] Takuya Inokuchi et al.. Arch Oral Biol. 2025. Phellodendron bark extract and berberine chloride suppress microbiome dysbiosis in a saliva-derived in vitro microcosm biofilm model. doi:10.1016/j.archoralbio.2025.106231 PubMed
- [11] Lin Yin et al.. Front Nutr. 2025. The role of traditional Chinese medicine in modulating gut microbiota to alleviating insulin resistance in polycystic ovary syndrome. doi:10.3389/fnut.2025.1700612 PubMed
- [12] Mengxia Wang et al.. Biomed Pharmacother. 2024. Integration of microbiome, metabolomics and transcriptome for in-depth understanding of berberine attenuates AOM/DSS-induced colitis-associated colorectal cancer. doi:10.1016/j.biopha.2024.117292 PubMed
- [13] Florentina Ionita-Radu et al.. Int J Mol Sci. 2024. Berberine Effects in Pre-Fibrotic Stages of Non-Alcoholic Fatty Liver Disease-Clinical and Pre-Clinical Overview and Systematic Review of the Literature. doi:10.3390/ijms25084201 PubMed
- [14] Lisheng Chen et al.. Front Pharmacol. 2024. Elucidation of the mechanism of berberine against gastric mucosa injury in a rat model with chronic atrophic gastritis based on … doi:10.3389/fphar.2024.1499753 PubMed
- [15] Hao Yang et al.. Hepatol Commun. 2024. Berberine alleviates concanavalin A-induced autoimmune hepatitis in mice by modulating the gut microbiota. doi:10.1097/HC9.0000000000000381 PubMed
- [16] Yazhi Qi et al.. Front Microbiol. 2024. Total Alkaloids of Rhizoma Corydalis regulates gut microbiota and restores gut immune barrier to ameliorate cognitive dysfunction in diabetic rats. doi:10.3389/fmicb.2024.1456406 PubMed
- [17] Wenjia Wang et al.. Front Microbiol. 2024. Intestinal and hepatic benefits of BBR-EVO on DSS-induced experimental colitis in mice. doi:10.3389/fmicb.2024.1428327 PubMed
- [18] Devi Datt Joshi et al.. Indian J Microbiol. 2024. Relevance of Indian Traditional Herbal Brews for Gut Microbiota Balance. doi:10.1007/s12088-024-01251-4 PubMed
- [19] Zikai Wang et al.. Gut Microbes. 2023. Colorectal cancer and gut microbiota studies in China. doi:10.1080/19490976.2023.2236364 PubMed
- [20] Xiongjie Sun et al.. Biomed Pharmacother. 2023. Berberine improves DSS-induced colitis in mice by modulating the fecal-bacteria-related bile acid metabolism. doi:10.1016/j.biopha.2023.115430 PubMed
- [21] Haitao Chen et al.. Int J Biol Sci. 2023. Berberine inhibits high fat diet-associated colorectal cancer through modulation of the gut microbiota-mediated lysophosphatidylcholine. doi:10.7150/ijbs.81824 PubMed
- [22] Qiao Zhang et al.. J Ethnopharmacol. 2023. Role of herbal medicine and gut microbiota in the prevention and treatment of obesity. doi:10.1016/j.jep.2022.116127 PubMed
- [23] Tessa Dehau et al.. Front Pharmacol. 2023. Berberine-microbiota interplay: orchestrating gut health through modulation of the gut microbiota and metabolic transformation into bioactive metabolites. doi:10.3389/fphar.2023.1281090 PubMed
- [24] Leila Khalili et al.. Int J Mol Sci. 2023. Effects of Berries, Phytochemicals, and Probiotics on Atherosclerosis through Gut Microbiota Modification: A Meta-Analysis of Animal Studies. doi:10.3390/ijms24043084 PubMed
- [25] Ayoub Amssayef et al.. Curr Pharm Des. 2023. Alkaloids as Promising Agents for the Management of Insulin Resistance: A Review. doi:10.2174/0113816128270340231121043038 PubMed
- [26] Takuma Okuda et al.. J Oral Biosci. 2023. An in vitro study of the effects of Phellodendron bark extract and berberine chloride on periodontal pathogenic bacteria in the … doi:10.1016/j.job.2022.11.003 PubMed
- [27] Jindong Zhang et al.. J Neurogastroenterol Motil. 2023. Distinct Effects of Non-absorbed Agents Rifaximin and Berberine on the Microbiota-Gut-Brain Axis in Dysbiosis-induced Visceral Hypersensitivity in Rats. doi:10.5056/jnm22182 PubMed
- [28] Ting-Wei Zhu et al.. Clin Exp Pharmacol Physiol. 2023. Berberine interacts with gut microbiota and its potential therapy for polycystic ovary syndrome. doi:10.1111/1440-1681.13814 PubMed
- [29] Awad A Shehata et al.. Microorganisms. 2022. Probiotics, Prebiotics, and Phytogenic Substances for Optimizing Gut Health in Poultry. doi:10.3390/microorganisms10020395 PubMed
- [30] Mingyue Zhong et al.. Food Funct. 2022. Astragalus mongholicus polysaccharides ameliorate hepatic lipid accumulation and inflammation as well as modulate gut microbiota in NAFLD rats. doi:10.1039/d2fo01009g PubMed
- [31] Qiang Sun et al.. Phytomedicine. 2022. Berberine suppresses colorectal cancer by regulation of Hedgehog signaling pathway activity and gut microbiota. doi:10.1016/j.phymed.2022.154227 PubMed
- [32] Mei Yang et al.. Biomater Sci. 2022. An oral pH-activated "nano-bomb" carrier combined with berberine by regulating gene silencing and gut microbiota for site-specific treatment of ulcerative … doi:10.1039/d1bm01765a PubMed
- [33] Xueying Li et al.. Microbiol Spectr. 2022. Berberine Depresses Inflammation and Adjusts Smooth Muscle to Ameliorate Ulcerative Colitis of Cats by Regulating Gut Microbiota. doi:10.1128/spectrum.03207-22 PubMed
- [34] Yufan Dai et al.. Braz J Med Biol Res. 2022. The combination of berberine and evodiamine ameliorates high-fat diet-induced non-alcoholic fatty liver disease associated with modulation of gut microbiota in … doi:10.1590/1414-431X2022e12096 PubMed
- [35] Qinmei Li et al.. Pharmacol Res. 2021. Main active components of Jiawei Gegen Qinlian decoction protects against ulcerative colitis under different dietary environments in a gut microbiota-dependent … doi:10.1016/j.phrs.2021.105694 PubMed
- [36] Wanghui Jing et al.. Pharmacol Res. 2021. Berberine improves colitis by triggering AhR activation by microbial tryptophan catabolites. doi:10.1016/j.phrs.2020.105358 PubMed
- [37] Jin-Dong Zhang et al.. Acta Pharmacol Sin. 2021. Berberine alleviates visceral hypersensitivity in rats by altering gut microbiome and suppressing spinal microglial activation. doi:10.1038/s41401-020-00601-4 PubMed
- [38] Xiangbing Shu et al.. Front Pharmacol. 2021. Berberine Alleviates Non-alcoholic Steatohepatitis Through Modulating Gut Microbiota Mediated Intestinal FXR Activation. doi:10.3389/fphar.2021.750826 PubMed
- [39] Zhe Han et al.. Front Immunol. 2021. The Potential Prebiotic Berberine Combined With Methimazole Improved the Therapeutic Effect of Graves' Disease Patients Through Regulating the Intestinal Microbiome. doi:10.3389/fimmu.2021.826067 PubMed
- [40] Phillip B Hylemon et al.. Compr Physiol. 2021. Bile Acids, Gut Microbiome and the Road to Fatty Liver Disease. doi:10.1002/cphy.c210024 PubMed
- [41] Pamela Senesi et al.. Int J Mol Sci. 2021. Diabetes Mellitus and Cardiovascular Diseases: Nutraceutical Interventions Related to Caloric Restriction. doi:10.3390/ijms22157772 PubMed
- [42] Priyankar Dey. Pharmacol Res. 2020. Targeting gut barrier dysfunction with phytotherapies: Effective strategy against chronic diseases. doi:10.1016/j.phrs.2020.105135 PubMed
- [43] Noriko Shinjyo et al.. J Integr Med. 2020. Berberine for prevention of dementia associated with diabetes and its comorbidities: A systematic review. doi:10.1016/j.joim.2020.01.004 PubMed
- [44] Priyankar Dey. Pharmacol Res. 2019. Gut microbiota in phytopharmacology: A comprehensive overview of concepts, reciprocal interactions, biotransformations and mode of actions. doi:10.1016/j.phrs.2019.104367 PubMed
- [45] Shi-Jun Yue et al.. Am J Physiol Endocrinol Metab. 2019. Berberine alleviates insulin resistance by reducing peripheral branched-chain amino acids. doi:10.1152/ajpendo.00256.2018 PubMed
- [46] Shi-Jun Yue et al.. Biomed Pharmacother. 2019. Berberine treatment-emergent mild diarrhea associated with gut microbiota dysbiosis. doi:10.1016/j.biopha.2019.109002 PubMed
- [47] Sheng Wang et al.. Sci Rep. 2019. Jatrorrhizine Balances the Gut Microbiota and Reverses Learning and Memory Deficits in APP/PS1 transgenic mice. doi:10.1038/s41598-019-56149-9 PubMed
- [48] Wang Anlu et al.. Pharmacol Res. 2019. Using herbal medicine to target the "microbiota-metabolism-immunity" axis as possible therapy for cardiovascular disease. doi:10.1016/j.phrs.2019.02.018 PubMed
- [49] Chenjie Qin et al.. Sci China Life Sci. 2018. Microbiota transplantation reveals beneficial impact of berberine on hepatotoxicity by improving gut homeostasis. doi:10.1007/s11427-017-9202-0 PubMed
- [50] Benjamin I Brown. Altern Ther Health Med. 2017. Nutritional Management of Metabolic Endotoxemia: A Clinical Review. PubMed
FDA 免责声明: 这些声明未经美国食品药品监督管理局（FDA）评估。本网站上的产品和信息无意用于诊断、治疗、治愈或预防任何疾病。所展示的证据等级基于我们对已发表的同行评审研究的分析，不构成医疗建议。在开始任何补充剂方案之前，请务必咨询您的医疗保健提供者。